MedTrace Logo

First Line Chemotherapy for Advanced Cancer

NCT01980810 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-06-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

Interventions

DRUG

albumin-bounded paclitaxel

200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles

DRUG

S-1

40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Lin Yang, MD · Department of medical oncology,Cancer hospital and institute,CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-02-28
Completion
2016-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01980810 on ClinicalTrials.gov